Provexis and DSM scooped the Best Partnership at the Functional Ingredients Editor’s Choice Awards at Engredea 2012. Licensed by Provexis to DSM Nutritional Products in 2010, the technology is currently available in a syrup format in a number of commercially available products including RelaxZen in the US and Biocol in Spain. A powder format is now being developed by DSM, opening up a route to market for dietary supplement manufacturers. Provexis researchers are also developing a gel version of the ingredient for use in sports applications.
Fruitflow is a natural, scientifically-substantiated breakthrough ingredient for healthy blood flow which works by preventing and reversing platelet aggregation. Abnormal blood platelet aggregation can be described as a ‘stickiness’ or spikiness of platelets in the blood vessel. This change in the formation of the blood platelets increases the risk of blood clots and of cardiovascular events such as heart attack, stroke or arterial disease.
Fruitflow actively smoothes blood platelets, facilitating blood flow around the body. Effectiveness of the technology has been established by rigorous scientific evaluation, leading to the first Article 13 (5) health claim substantiated by the European Food Safety Authority (EFSA). It has also been given GRAS status by the Food and Drug Administration (FDA) in the US. This approval from independent industry bodies gives nutraceutical manufacturers confidence that the health benefits they are promoting are valid and backed by strong science.
Stephen Moon, Chief Executive Officer of Provexis plc, commented: “We are delighted with this recognition of our successful partnership with DSM. From our experience with the development and commercialisation of Fruitflow® and DSM’s market-leading position in nutritional products, the synergy between the two companies has allowed us to create highly functional and profitable health and nutrition ingredients.”